Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Rinaldi

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Brain : a Journal of Neurology|August 30, 2023
Reply: Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotationStephen Keddie, Duncan Smyth, Ryan Y S Keh, et al.
BMC Neurology|March 7, 2026
Clinical and economic outcomes of therapeutic plasma exchange and intravenous immunoglobulin for treating adults with autoimmune neurological disorders: a systematic review and meta-analysisCatherine Kimber, Reem Malouf, Javad Javan, et al.
The Journal of Clinical Investigation|June 7, 2022
Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-Barré syndrome mouse modelRhona McGonigal, Clare I Campbell, Jennifer A Barrie, et al.
Journal of the Peripheral Nervous System : JPNS|August 19, 2025
Real-World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic LandscapeLuis Querol, Simon Rinaldi, Andras Borsi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 17, 2021
IgG<sub>1</sub> pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortalityJanev Fehmi, Alexander J Davies, Jon Walters, et al.
Plos One|December 21, 2013
Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndromeSimon Rinaldi, Kathryn M Brennan, Gabriela Kalna, et al.
Brain Communications|July 9, 2024
Pathologic <i>RFC1</i> repeat expansions do not contribute to the development of inflammatory neuropathiesSara Nagy, Aisling Carr, Magdalena Mroczek, et al.
Brain : a Journal of Neurology|October 7, 2025
Enhanced adenoviral reactivity in Guillain-Barré syndrome after SARS-CoV-2 infection and vaccinationRoberto Bellanti, Ana Candalija Iserte, Claire Bergstrom Johnson, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 21, 2021
Serum Contactin-1 in CIDP: A Cross-Sectional StudyLuuk Wieske, Lorena Martín-Aguilar, Janev Fehmi, et al.
Annals of Clinical and Translational Neurology|May 16, 2018
Seronegative antibody-mediated neurology after immune checkpoint inhibitorsRobert Wilson, David A Menassa, Alexander J Davies, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Brain : a Journal of Neurology|August 30, 2023
Reply: Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotationStephen Keddie, Duncan Smyth, Ryan Y S Keh, et al.
BMC Neurology|March 7, 2026
Clinical and economic outcomes of therapeutic plasma exchange and intravenous immunoglobulin for treating adults with autoimmune neurological disorders: a systematic review and meta-analysisCatherine Kimber, Reem Malouf, Javad Javan, et al.
The Journal of Clinical Investigation|June 7, 2022
Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-Barré syndrome mouse modelRhona McGonigal, Clare I Campbell, Jennifer A Barrie, et al.
Journal of the Peripheral Nervous System : JPNS|August 19, 2025
Real-World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic LandscapeLuis Querol, Simon Rinaldi, Andras Borsi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 17, 2021
IgG<sub>1</sub> pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortalityJanev Fehmi, Alexander J Davies, Jon Walters, et al.
Plos One|December 21, 2013
Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndromeSimon Rinaldi, Kathryn M Brennan, Gabriela Kalna, et al.
Brain Communications|July 9, 2024
Pathologic <i>RFC1</i> repeat expansions do not contribute to the development of inflammatory neuropathiesSara Nagy, Aisling Carr, Magdalena Mroczek, et al.
Brain : a Journal of Neurology|October 7, 2025
Enhanced adenoviral reactivity in Guillain-Barré syndrome after SARS-CoV-2 infection and vaccinationRoberto Bellanti, Ana Candalija Iserte, Claire Bergstrom Johnson, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 21, 2021
Serum Contactin-1 in CIDP: A Cross-Sectional StudyLuuk Wieske, Lorena Martín-Aguilar, Janev Fehmi, et al.
Annals of Clinical and Translational Neurology|May 16, 2018
Seronegative antibody-mediated neurology after immune checkpoint inhibitorsRobert Wilson, David A Menassa, Alexander J Davies, et al.
Pageof 7